Catalog No.: PC-38626Not For Human Use, Lab Use Only.
IKAM-1 (Compound 39-100) is an orally bioavailable, small-molecule IKKβ activation modulator (IKAM) that selectively targets MAP3K1, inhibits TNF-α-induced IKKβ-mediated NF-κB activation in A549 cells with IC50 of 4.7 uM.
IKAM-1 (Compound 39-100) is an orally bioavailable, small-molecule IKKβ activation modulator (IKAM) that selectively targets MAP3K1, inhibits TNF-α-induced IKKβ-mediated NF-κB activation in A549 cells with IC50 of 4.7 uM.
IKAM-1 (Compound 39-100) selectively binds to MAP3K1 and MAP3K12, inhibits MAP3K1 with IC50 of 4.2 uM, does not inhibit IKKβ but selectively inhibits MAP3K1 with micromolar potency in PANC1 cell lysates.
IKAM-1 (Compound 39-100) inhibits MAP3K1-mediated IKKβ phosphorylation and reduced levels of p-IKKβ in with an IC50 value of 2.3 uM, inhibits the growth of PC lines with lowmicromolar potencies.
IKAM-1 (Compound 39-100) reduces activated IKKβ levels, inhibits tumor growth, and reduces metastasis in mice pancreatic tumor models.
